 Richard Schulick
Concepts (913)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 180 | 2025 | 941 | 16.830 |
Why?
| | Pancreaticoduodenectomy | 65 | 2025 | 163 | 7.720 |
Why?
| | Adenocarcinoma | 77 | 2025 | 934 | 6.430 |
Why?
| | Carcinoma, Pancreatic Ductal | 51 | 2024 | 289 | 5.790 |
Why?
| | Pancreatectomy | 57 | 2025 | 249 | 5.430 |
Why?
| | Liver Neoplasms | 56 | 2024 | 783 | 3.650 |
Why?
| | Bile Duct Neoplasms | 14 | 2024 | 122 | 2.340 |
Why?
| | Hepatectomy | 38 | 2024 | 245 | 2.220 |
Why?
| | Neoadjuvant Therapy | 28 | 2025 | 404 | 2.190 |
Why?
| | Neuroendocrine Tumors | 13 | 2025 | 118 | 2.180 |
Why?
| | Cholangiocarcinoma | 12 | 2024 | 103 | 2.060 |
Why?
| | Common Bile Duct Neoplasms | 10 | 2025 | 30 | 1.880 |
Why?
| | Laparoscopy | 15 | 2024 | 464 | 1.860 |
Why?
| | Pancreatic Cyst | 12 | 2022 | 60 | 1.850 |
Why?
| | Survival Rate | 61 | 2025 | 1972 | 1.620 |
Why?
| | General Surgery | 7 | 2021 | 170 | 1.610 |
Why?
| | Neoplasm Recurrence, Local | 28 | 2024 | 1057 | 1.580 |
Why?
| | Stomach Neoplasms | 7 | 2024 | 126 | 1.530 |
Why?
| | Colorectal Neoplasms | 21 | 2014 | 797 | 1.510 |
Why?
| | Humans | 348 | 2025 | 136899 | 1.460 |
Why?
| | Pancreas | 16 | 2023 | 328 | 1.410 |
Why?
| | Carcinoma, Neuroendocrine | 8 | 2023 | 39 | 1.410 |
Why?
| | Prognosis | 69 | 2024 | 4011 | 1.390 |
Why?
| | Neoplasm Staging | 42 | 2024 | 1376 | 1.390 |
Why?
| | Cancer Vaccines | 8 | 2024 | 173 | 1.380 |
Why?
| | Aged | 173 | 2025 | 23641 | 1.330 |
Why?
| | Middle Aged | 187 | 2025 | 33118 | 1.310 |
Why?
| | Retrospective Studies | 112 | 2025 | 15514 | 1.310 |
Why?
| | Bile Ducts, Intrahepatic | 11 | 2012 | 78 | 1.270 |
Why?
| | Postoperative Complications | 29 | 2025 | 2627 | 1.220 |
Why?
| | Ampulla of Vater | 11 | 2025 | 42 | 1.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 22 | 2025 | 1689 | 1.190 |
Why?
| | Adenocarcinoma, Mucinous | 9 | 2023 | 80 | 1.160 |
Why?
| | Mesenteric Veins | 6 | 2025 | 21 | 1.120 |
Why?
| | Portal Vein | 8 | 2025 | 117 | 1.110 |
Why?
| | Female | 227 | 2025 | 72703 | 1.070 |
Why?
| | Male | 212 | 2025 | 67308 | 1.070 |
Why?
| | Chemotherapy, Adjuvant | 24 | 2025 | 392 | 1.030 |
Why?
| | Pancreatic Fistula | 6 | 2022 | 29 | 0.950 |
Why?
| | Carcinoma, Hepatocellular | 11 | 2016 | 359 | 0.950 |
Why?
| | Aged, 80 and over | 79 | 2025 | 7552 | 0.940 |
Why?
| | Pancreatic Ducts | 7 | 2012 | 81 | 0.930 |
Why?
| | Biomarkers, Tumor | 20 | 2024 | 1271 | 0.900 |
Why?
| | Robotics | 3 | 2015 | 96 | 0.890 |
Why?
| | Neoplasms, Second Primary | 4 | 2019 | 115 | 0.850 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2022 | 181 | 0.840 |
Why?
| | Early Detection of Cancer | 6 | 2020 | 419 | 0.790 |
Why?
| | Colonic Neoplasms | 9 | 2024 | 258 | 0.790 |
Why?
| | Patient Care Team | 7 | 2021 | 624 | 0.780 |
Why?
| | Quality-Adjusted Life Years | 2 | 2013 | 111 | 0.780 |
Why?
| | Combined Modality Therapy | 19 | 2024 | 1240 | 0.740 |
Why?
| | Follow-Up Studies | 37 | 2024 | 5126 | 0.730 |
Why?
| | Carcinoma | 5 | 2018 | 237 | 0.710 |
Why?
| | Internship and Residency | 4 | 2021 | 1131 | 0.700 |
Why?
| | Adult | 117 | 2025 | 37595 | 0.690 |
Why?
| | Treatment Outcome | 63 | 2025 | 10768 | 0.670 |
Why?
| | Listeria monocytogenes | 5 | 2012 | 126 | 0.670 |
Why?
| | Faculty, Medical | 2 | 2018 | 283 | 0.670 |
Why?
| | Learning Curve | 2 | 2024 | 72 | 0.660 |
Why?
| | Survival Analysis | 28 | 2024 | 1320 | 0.660 |
Why?
| | Lymphatic Metastasis | 24 | 2024 | 349 | 0.660 |
Why?
| | Tomography, X-Ray Computed | 24 | 2021 | 2670 | 0.660 |
Why?
| | Cyclophosphamide | 6 | 2024 | 246 | 0.660 |
Why?
| | Cost-Benefit Analysis | 2 | 2013 | 592 | 0.650 |
Why?
| | Tumor Microenvironment | 11 | 2025 | 682 | 0.640 |
Why?
| | Healthcare Disparities | 5 | 2014 | 632 | 0.640 |
Why?
| | Thrombelastography | 4 | 2024 | 153 | 0.630 |
Why?
| | Stents | 5 | 2011 | 524 | 0.620 |
Why?
| | Fluorouracil | 15 | 2025 | 213 | 0.620 |
Why?
| | Adenoma | 6 | 2025 | 229 | 0.620 |
Why?
| | Neoplasms | 12 | 2025 | 2655 | 0.610 |
Why?
| | Pancreatic Diseases | 7 | 2019 | 72 | 0.610 |
Why?
| | Immunotherapy | 13 | 2024 | 645 | 0.600 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 22 | 0.600 |
Why?
| | Proportional Hazards Models | 20 | 2023 | 1262 | 0.590 |
Why?
| | Vascular Surgical Procedures | 6 | 2025 | 298 | 0.590 |
Why?
| | Mentors | 3 | 2021 | 192 | 0.560 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 44 | 0.560 |
Why?
| | Databases, Factual | 9 | 2024 | 1345 | 0.550 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2008 | 38 | 0.550 |
Why?
| | Practice Patterns, Physicians' | 9 | 2025 | 1310 | 0.530 |
Why?
| | Lymph Node Excision | 4 | 2024 | 174 | 0.530 |
Why?
| | Hospitals | 3 | 2019 | 678 | 0.530 |
Why?
| | Leadership | 2 | 2018 | 376 | 0.520 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 113 | 0.520 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2024 | 221 | 0.520 |
Why?
| | Adrenalectomy | 2 | 2006 | 68 | 0.510 |
Why?
| | Gallbladder Neoplasms | 5 | 2024 | 23 | 0.500 |
Why?
| | Lung Neoplasms | 8 | 2023 | 2490 | 0.500 |
Why?
| | Cholecystectomy | 4 | 2014 | 60 | 0.490 |
Why?
| | Education, Medical, Continuing | 2 | 2015 | 126 | 0.490 |
Why?
| | Antineoplastic Agents | 11 | 2021 | 2140 | 0.490 |
Why?
| | Carcinoma, Papillary | 6 | 2017 | 81 | 0.480 |
Why?
| | Quality Assurance, Health Care | 2 | 2015 | 324 | 0.470 |
Why?
| | Benchmarking | 3 | 2021 | 184 | 0.470 |
Why?
| | Neoplasm Invasiveness | 21 | 2025 | 510 | 0.460 |
Why?
| | Cholelithiasis | 1 | 2014 | 37 | 0.460 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 3 | 2016 | 211 | 0.450 |
Why?
| | Peritoneal Neoplasms | 3 | 2024 | 94 | 0.450 |
Why?
| | Bile Ducts, Extrahepatic | 3 | 2012 | 22 | 0.450 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 21 | 0.450 |
Why?
| | Membrane Glycoproteins | 4 | 2025 | 501 | 0.450 |
Why?
| | Lymphedema | 1 | 2014 | 26 | 0.440 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 302 | 0.440 |
Why?
| | Biomedical Research | 2 | 2013 | 688 | 0.440 |
Why?
| | Pheochromocytoma | 3 | 2013 | 58 | 0.430 |
Why?
| | Metastasectomy | 2 | 2024 | 20 | 0.430 |
Why?
| | SEER Program | 11 | 2011 | 216 | 0.430 |
Why?
| | Radiosurgery | 3 | 2024 | 346 | 0.430 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2014 | 114 | 0.430 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2013 | 89 | 0.420 |
Why?
| | Liver Neoplasms, Experimental | 4 | 2014 | 31 | 0.420 |
Why?
| | Esophageal Neoplasms | 4 | 2023 | 323 | 0.420 |
Why?
| | Cytoreduction Surgical Procedures | 3 | 2024 | 63 | 0.420 |
Why?
| | Genetic Predisposition to Disease | 7 | 2018 | 2416 | 0.410 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 121 | 0.410 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 392 | 0.410 |
Why?
| | Catheter Ablation | 11 | 2012 | 348 | 0.410 |
Why?
| | Risk Assessment | 19 | 2020 | 3432 | 0.400 |
Why?
| | Nomograms | 3 | 2022 | 54 | 0.400 |
Why?
| | Leucovorin | 6 | 2025 | 83 | 0.400 |
Why?
| | Deoxycytidine | 7 | 2025 | 176 | 0.390 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2009 | 18 | 0.390 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 75 | 0.380 |
Why?
| | Rectal Neoplasms | 5 | 2017 | 149 | 0.380 |
Why?
| | Incidental Findings | 7 | 2021 | 87 | 0.380 |
Why?
| | Kaplan-Meier Estimate | 19 | 2018 | 892 | 0.370 |
Why?
| | Cystadenoma, Serous | 4 | 2020 | 21 | 0.370 |
Why?
| | Research Personnel | 1 | 2013 | 168 | 0.370 |
Why?
| | Immunohistochemistry | 20 | 2019 | 1739 | 0.370 |
Why?
| | Diagnosis, Differential | 9 | 2022 | 1484 | 0.370 |
Why?
| | Carcinoma, Islet Cell | 3 | 2006 | 4 | 0.370 |
Why?
| | Cohort Studies | 21 | 2024 | 5711 | 0.370 |
Why?
| | Sigmoid Neoplasms | 1 | 2011 | 5 | 0.360 |
Why?
| | Vascular Neoplasms | 4 | 2020 | 18 | 0.360 |
Why?
| | Interleukin-2 | 4 | 2007 | 455 | 0.360 |
Why?
| | Solitary Fibrous Tumors | 1 | 2011 | 5 | 0.360 |
Why?
| | Palliative Care | 6 | 2012 | 737 | 0.360 |
Why?
| | Predictive Value of Tests | 17 | 2024 | 2030 | 0.360 |
Why?
| | Mice, Inbred BALB C | 12 | 2021 | 1271 | 0.350 |
Why?
| | United States | 35 | 2024 | 14595 | 0.350 |
Why?
| | Hepatic Artery | 5 | 2020 | 61 | 0.350 |
Why?
| | Gamma Rays | 2 | 2021 | 56 | 0.340 |
Why?
| | Patient Care Planning | 4 | 2018 | 154 | 0.340 |
Why?
| | Lymph Nodes | 8 | 2024 | 493 | 0.340 |
Why?
| | Breast Neoplasms | 3 | 2024 | 2243 | 0.340 |
Why?
| | Cyst Fluid | 4 | 2022 | 25 | 0.330 |
Why?
| | Positron-Emission Tomography | 7 | 2008 | 299 | 0.330 |
Why?
| | MAP Kinase Kinase 4 | 2 | 2006 | 29 | 0.330 |
Why?
| | Integrin alpha2 | 1 | 2009 | 3 | 0.330 |
Why?
| | Disease-Free Survival | 13 | 2023 | 690 | 0.320 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2023 | 78 | 0.320 |
Why?
| | Mice | 29 | 2025 | 17775 | 0.310 |
Why?
| | Cystadenocarcinoma, Mucinous | 3 | 2015 | 14 | 0.310 |
Why?
| | Referral and Consultation | 4 | 2024 | 779 | 0.310 |
Why?
| | Abdominal Abscess | 2 | 2011 | 27 | 0.310 |
Why?
| | Octreotide | 1 | 2009 | 26 | 0.310 |
Why?
| | Length of Stay | 10 | 2021 | 1203 | 0.310 |
Why?
| | Mutation | 11 | 2016 | 3948 | 0.310 |
Why?
| | Adenoma, Islet Cell | 2 | 2006 | 8 | 0.310 |
Why?
| | Risk Factors | 31 | 2024 | 10313 | 0.310 |
Why?
| | CA-19-9 Antigen | 4 | 2024 | 22 | 0.300 |
Why?
| | Liver Transplantation | 6 | 2024 | 870 | 0.300 |
Why?
| | Klatskin Tumor | 3 | 2021 | 14 | 0.300 |
Why?
| | Radiotherapy, Adjuvant | 11 | 2024 | 218 | 0.300 |
Why?
| | Time Factors | 20 | 2021 | 6802 | 0.300 |
Why?
| | Internationality | 2 | 2020 | 155 | 0.300 |
Why?
| | Chemoradiotherapy | 6 | 2022 | 225 | 0.300 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 1999 | 63 | 0.300 |
Why?
| | Robotic Surgical Procedures | 2 | 2021 | 126 | 0.300 |
Why?
| | Choledochal Cyst | 1 | 2008 | 19 | 0.290 |
Why?
| | Duodenostomy | 1 | 2007 | 3 | 0.290 |
Why?
| | Jejunostomy | 1 | 2007 | 12 | 0.290 |
Why?
| | Operative Time | 3 | 2024 | 142 | 0.280 |
Why?
| | Digestive System Surgical Procedures | 3 | 2019 | 106 | 0.280 |
Why?
| | Pain, Postoperative | 2 | 2021 | 271 | 0.280 |
Why?
| | Biliary Tract Surgical Procedures | 3 | 2021 | 25 | 0.270 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2016 | 25 | 0.270 |
Why?
| | Gastrectomy | 2 | 2024 | 120 | 0.270 |
Why?
| | Biomarkers | 5 | 2022 | 4148 | 0.270 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2024 | 151 | 0.270 |
Why?
| | Cushing Syndrome | 1 | 2006 | 10 | 0.270 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2017 | 43 | 0.270 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2025 | 209 | 0.270 |
Why?
| | Hyperamylasemia | 2 | 2022 | 3 | 0.260 |
Why?
| | von Hippel-Lindau Disease | 1 | 2006 | 12 | 0.260 |
Why?
| | Animals | 39 | 2025 | 36915 | 0.260 |
Why?
| | Anastomosis, Surgical | 4 | 2015 | 154 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.250 |
Why?
| | Interdisciplinary Communication | 3 | 2021 | 192 | 0.250 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2006 | 142 | 0.250 |
Why?
| | Prospective Studies | 23 | 2024 | 7543 | 0.250 |
Why?
| | Esophagectomy | 2 | 2022 | 131 | 0.250 |
Why?
| | DNA Helicases | 3 | 2012 | 150 | 0.250 |
Why?
| | Liver | 6 | 2020 | 1937 | 0.250 |
Why?
| | Carcinoma in Situ | 3 | 2012 | 49 | 0.250 |
Why?
| | Endosonography | 4 | 2018 | 152 | 0.240 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2018 | 143 | 0.240 |
Why?
| | Pancreatitis | 3 | 2022 | 132 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 3 | 2013 | 919 | 0.240 |
Why?
| | Precancerous Conditions | 4 | 2011 | 170 | 0.240 |
Why?
| | Arteries | 2 | 2019 | 269 | 0.240 |
Why?
| | Cell Proliferation | 8 | 2021 | 2471 | 0.240 |
Why?
| | Chemoembolization, Therapeutic | 4 | 2012 | 91 | 0.240 |
Why?
| | Cell Line, Tumor | 13 | 2025 | 3396 | 0.240 |
Why?
| | Hospital Mortality | 10 | 2020 | 901 | 0.240 |
Why?
| | Genetic Engineering | 1 | 2006 | 92 | 0.240 |
Why?
| | Publishing | 1 | 2007 | 146 | 0.240 |
Why?
| | Membrane Proteins | 4 | 2021 | 1167 | 0.230 |
Why?
| | Lectins, C-Type | 2 | 2024 | 72 | 0.230 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2016 | 12 | 0.230 |
Why?
| | Immunotherapy, Adoptive | 2 | 2025 | 322 | 0.230 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 218 | 0.230 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 1994 | 137 | 0.230 |
Why?
| | Smad4 Protein | 4 | 2013 | 38 | 0.230 |
Why?
| | Biliary Tract Neoplasms | 4 | 2006 | 30 | 0.220 |
Why?
| | Baltimore | 5 | 2018 | 58 | 0.220 |
Why?
| | Tumor Cells, Cultured | 6 | 2021 | 950 | 0.220 |
Why?
| | T-Lymphocytes | 4 | 2024 | 1996 | 0.220 |
Why?
| | Perioperative Care | 2 | 2024 | 182 | 0.220 |
Why?
| | Hepatoblastoma | 1 | 2024 | 46 | 0.220 |
Why?
| | Cystadenoma, Mucinous | 2 | 2015 | 14 | 0.210 |
Why?
| | Quality Improvement | 3 | 2023 | 1154 | 0.210 |
Why?
| | Immunity | 2 | 2021 | 145 | 0.210 |
Why?
| | Quality of Life | 6 | 2020 | 2847 | 0.210 |
Why?
| | Reoperation | 6 | 2016 | 568 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2025 | 857 | 0.210 |
Why?
| | Chi-Square Distribution | 8 | 2015 | 533 | 0.200 |
Why?
| | Nuclear Proteins | 4 | 2012 | 703 | 0.200 |
Why?
| | Somatostatinoma | 1 | 2002 | 1 | 0.200 |
Why?
| | Genes, Tumor Suppressor | 5 | 2011 | 86 | 0.200 |
Why?
| | Proto-Oncogene Proteins | 6 | 2012 | 646 | 0.200 |
Why?
| | Splenectomy | 3 | 2020 | 62 | 0.200 |
Why?
| | Ephrin-B2 | 2 | 2021 | 51 | 0.200 |
Why?
| | Patient Safety | 3 | 2021 | 305 | 0.200 |
Why?
| | Immunologic Factors | 2 | 2018 | 239 | 0.200 |
Why?
| | Benzamides | 3 | 2008 | 218 | 0.190 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 202 | 0.190 |
Why?
| | Multivariate Analysis | 9 | 2016 | 1524 | 0.190 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 2 | 2012 | 11 | 0.190 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.190 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 413 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 27 | 0.190 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.190 |
Why?
| | Carcinoembryonic Antigen | 5 | 2015 | 39 | 0.190 |
Why?
| | Incidence | 7 | 2019 | 2783 | 0.180 |
Why?
| | Quinazolines | 3 | 2013 | 249 | 0.180 |
Why?
| | Lymphocytes | 2 | 2020 | 393 | 0.180 |
Why?
| | Paternalism | 1 | 2021 | 4 | 0.180 |
Why?
| | Fibrosis | 3 | 2021 | 552 | 0.180 |
Why?
| | Hospitals, Teaching | 3 | 2018 | 116 | 0.180 |
Why?
| | Albumins | 3 | 2025 | 114 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 31 | 0.180 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 53 | 0.180 |
Why?
| | Recombinant Proteins | 2 | 2006 | 1357 | 0.180 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2020 | 73 | 0.180 |
Why?
| | Gastroenterology | 1 | 2023 | 181 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3710 | 0.170 |
Why?
| | Employment | 1 | 2022 | 177 | 0.170 |
Why?
| | Sarcoma | 2 | 2016 | 189 | 0.170 |
Why?
| | Access to Information | 1 | 2021 | 49 | 0.170 |
Why?
| | Oxycodone | 1 | 2021 | 44 | 0.170 |
Why?
| | Disease Progression | 8 | 2022 | 2744 | 0.170 |
Why?
| | Melanoma | 2 | 2022 | 757 | 0.170 |
Why?
| | Communication | 2 | 2021 | 872 | 0.170 |
Why?
| | Surgeons | 1 | 2025 | 296 | 0.170 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.170 |
Why?
| | Tattooing | 2 | 2010 | 14 | 0.170 |
Why?
| | Serotonin | 3 | 2012 | 324 | 0.170 |
Why?
| | Checklist | 1 | 2021 | 94 | 0.170 |
Why?
| | Body Composition | 1 | 2024 | 665 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 81 | 0.170 |
Why?
| | Sarcopenia | 2 | 2012 | 82 | 0.170 |
Why?
| | Tumor Burden | 6 | 2022 | 309 | 0.170 |
Why?
| | Pancreaticojejunostomy | 1 | 2020 | 8 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 173 | 0.170 |
Why?
| | Comprehension | 1 | 2022 | 176 | 0.170 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 111 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 799 | 0.170 |
Why?
| | Feasibility Studies | 5 | 2020 | 943 | 0.170 |
Why?
| | Health Literacy | 1 | 2022 | 168 | 0.160 |
Why?
| | Faculty | 1 | 2021 | 143 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2017 | 444 | 0.160 |
Why?
| | Operating Rooms | 1 | 2021 | 122 | 0.160 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 66 | 0.160 |
Why?
| | Algorithms | 2 | 2019 | 1695 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2023 | 248 | 0.160 |
Why?
| | Preoperative Care | 9 | 2018 | 356 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2021 | 147 | 0.160 |
Why?
| | Statistics, Nonparametric | 6 | 2011 | 434 | 0.160 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2012 | 429 | 0.160 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 75 | 0.160 |
Why?
| | Patient-Centered Care | 2 | 2022 | 523 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 178 | 0.160 |
Why?
| | Kidney Transplantation | 3 | 1997 | 695 | 0.160 |
Why?
| | Genetic Testing | 3 | 2018 | 453 | 0.160 |
Why?
| | Japan | 3 | 2025 | 116 | 0.160 |
Why?
| | Age Factors | 9 | 2022 | 3290 | 0.150 |
Why?
| | Radiology | 1 | 2021 | 181 | 0.150 |
Why?
| | Career Choice | 2 | 2018 | 215 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 37 | 0.150 |
Why?
| | Mice, Inbred C57BL | 8 | 2021 | 5766 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 212 | 0.150 |
Why?
| | Adolescent | 21 | 2022 | 21402 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2021 | 250 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 1999 | 65 | 0.150 |
Why?
| | Safety Management | 2 | 2010 | 119 | 0.150 |
Why?
| | Neoplasm Proteins | 3 | 2008 | 432 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 185 | 0.150 |
Why?
| | Analysis of Variance | 8 | 2013 | 1324 | 0.150 |
Why?
| | ras Proteins | 4 | 2012 | 151 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 190 | 0.150 |
Why?
| | Health Resources | 1 | 2019 | 122 | 0.150 |
Why?
| | Thalidomide | 1 | 2018 | 40 | 0.150 |
Why?
| | Flow Cytometry | 5 | 2019 | 1185 | 0.150 |
Why?
| | Europe | 4 | 2021 | 413 | 0.140 |
Why?
| | Sentinel Surveillance | 1 | 2018 | 47 | 0.140 |
Why?
| | Thrombophilia | 1 | 2018 | 85 | 0.140 |
Why?
| | Immunomodulation | 1 | 2018 | 98 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 798 | 0.140 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 77 | 0.140 |
Why?
| | Job Satisfaction | 2 | 2018 | 215 | 0.140 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2019 | 126 | 0.140 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 79 | 0.140 |
Why?
| | Signal Transduction | 9 | 2024 | 5077 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 3 | 2018 | 425 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1994 | 1092 | 0.140 |
Why?
| | Patient Compliance | 1 | 2021 | 586 | 0.130 |
Why?
| | Neutrophils | 3 | 2019 | 1237 | 0.130 |
Why?
| | DNA Mutational Analysis | 4 | 2016 | 401 | 0.130 |
Why?
| | Trastuzumab | 1 | 2017 | 101 | 0.130 |
Why?
| | Maryland | 4 | 2013 | 54 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2015 | 251 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 44 | 0.130 |
Why?
| | Societies, Medical | 2 | 2018 | 816 | 0.130 |
Why?
| | DNA Mismatch Repair | 1 | 2016 | 50 | 0.130 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 38 | 0.130 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 34 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 339 | 0.130 |
Why?
| | Ki-67 Antigen | 2 | 2013 | 112 | 0.130 |
Why?
| | Patient Selection | 4 | 2024 | 690 | 0.130 |
Why?
| | Telomere | 2 | 2012 | 280 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2020 | 344 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2018 | 225 | 0.130 |
Why?
| | Radiotherapy | 2 | 2019 | 201 | 0.130 |
Why?
| | Neoplasm Metastasis | 5 | 2012 | 658 | 0.120 |
Why?
| | Receptors, Immunologic | 1 | 2017 | 223 | 0.120 |
Why?
| | Viscera | 1 | 2015 | 17 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.120 |
Why?
| | Efficiency | 1 | 2016 | 98 | 0.120 |
Why?
| | Hepatitis | 2 | 2006 | 48 | 0.120 |
Why?
| | Neoplasm Grading | 5 | 2016 | 308 | 0.120 |
Why?
| | Cannabis | 1 | 2023 | 478 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2008 | 434 | 0.120 |
Why?
| | Constriction, Pathologic | 4 | 2011 | 242 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2025 | 5730 | 0.120 |
Why?
| | Young Adult | 16 | 2022 | 13157 | 0.120 |
Why?
| | Induction Chemotherapy | 1 | 2016 | 74 | 0.120 |
Why?
| | Cholestasis | 3 | 2011 | 231 | 0.120 |
Why?
| | Antigens, Neoplasm | 2 | 2024 | 321 | 0.120 |
Why?
| | Logistic Models | 5 | 2016 | 2060 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
| | Piperazines | 2 | 2008 | 349 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 391 | 0.120 |
Why?
| | Decision Making | 2 | 2012 | 897 | 0.120 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2010 | 94 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1400 | 0.120 |
Why?
| | MicroRNAs | 2 | 2012 | 703 | 0.120 |
Why?
| | Caregivers | 1 | 2022 | 865 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1079 | 0.120 |
Why?
| | Practice Guidelines as Topic | 3 | 2024 | 1575 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 578 | 0.110 |
Why?
| | Capecitabine | 4 | 2017 | 46 | 0.110 |
Why?
| | Perioperative Period | 2 | 2011 | 56 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 41 | 0.110 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 993 | 0.110 |
Why?
| | Genome | 2 | 2016 | 292 | 0.110 |
Why?
| | Spleen | 1 | 2016 | 516 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 51 | 0.110 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 270 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2014 | 171 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 849 | 0.110 |
Why?
| | Propensity Score | 3 | 2025 | 287 | 0.110 |
Why?
| | Pyrimidines | 2 | 2008 | 472 | 0.110 |
Why?
| | Mitotic Index | 1 | 2013 | 26 | 0.110 |
Why?
| | Metabolomics | 1 | 2019 | 675 | 0.110 |
Why?
| | Colectomy | 2 | 2012 | 99 | 0.110 |
Why?
| | Pancreas, Exocrine | 1 | 2013 | 7 | 0.110 |
Why?
| | Cystadenoma | 1 | 2013 | 6 | 0.110 |
Why?
| | Acinar Cells | 1 | 2013 | 13 | 0.110 |
Why?
| | Exome | 2 | 2011 | 231 | 0.110 |
Why?
| | Paclitaxel | 2 | 2025 | 231 | 0.110 |
Why?
| | Electronic Health Records | 1 | 2021 | 1018 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2016 | 445 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 139 | 0.100 |
Why?
| | Isoantigens | 1 | 1993 | 15 | 0.100 |
Why?
| | Survivors | 2 | 2015 | 482 | 0.100 |
Why?
| | Enzyme Precursors | 1 | 2013 | 15 | 0.100 |
Why?
| | Cell Movement | 3 | 2022 | 971 | 0.100 |
Why?
| | Graft Rejection | 2 | 1994 | 623 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2015 | 185 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2016 | 410 | 0.100 |
Why?
| | Cholangiography | 3 | 2007 | 16 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 1997 | 886 | 0.100 |
Why?
| | Protein C | 1 | 2013 | 59 | 0.100 |
Why?
| | Radiopharmaceuticals | 3 | 2008 | 178 | 0.100 |
Why?
| | Psoas Muscles | 1 | 2012 | 13 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2008 | 135 | 0.100 |
Why?
| | Tissue Array Analysis | 5 | 2011 | 57 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 2 | 2011 | 328 | 0.100 |
Why?
| | Biliopancreatic Diversion | 1 | 2012 | 1 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2011 | 790 | 0.100 |
Why?
| | Mice, Nude | 5 | 2020 | 696 | 0.100 |
Why?
| | Safety | 1 | 2014 | 341 | 0.100 |
Why?
| | Hemangioma | 1 | 2012 | 48 | 0.100 |
Why?
| | Carcinoma, Large Cell | 1 | 2012 | 16 | 0.100 |
Why?
| | Metoclopramide | 1 | 2012 | 19 | 0.100 |
Why?
| | Ataxia Telangiectasia | 1 | 2011 | 20 | 0.100 |
Why?
| | Papilloma, Intraductal | 1 | 2011 | 3 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 29 | 0.100 |
Why?
| | DNA Methylation | 4 | 2008 | 644 | 0.100 |
Why?
| | Biopsy, Needle | 3 | 2011 | 191 | 0.090 |
Why?
| | Radiography | 5 | 2016 | 834 | 0.090 |
Why?
| | Loss of Heterozygosity | 1 | 2012 | 51 | 0.090 |
Why?
| | Silk | 1 | 2011 | 2 | 0.090 |
Why?
| | Glycolipids | 1 | 2012 | 42 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2006 | 1242 | 0.090 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2011 | 7 | 0.090 |
Why?
| | Odds Ratio | 5 | 2016 | 1063 | 0.090 |
Why?
| | X Chromosome Inactivation | 2 | 2013 | 25 | 0.090 |
Why?
| | Hyalin | 1 | 2011 | 6 | 0.090 |
Why?
| | Hepatic Duct, Common | 1 | 2011 | 6 | 0.090 |
Why?
| | Injections, Intra-Arterial | 1 | 2011 | 27 | 0.090 |
Why?
| | Comorbidity | 5 | 2022 | 1611 | 0.090 |
Why?
| | Shock, Cardiogenic | 1 | 2012 | 63 | 0.090 |
Why?
| | Carcinoid Tumor | 1 | 2011 | 26 | 0.090 |
Why?
| | Cysts | 1 | 2012 | 111 | 0.090 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4281 | 0.090 |
Why?
| | Liver Cirrhosis | 3 | 2008 | 316 | 0.090 |
Why?
| | Gentamicins | 1 | 2011 | 54 | 0.090 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 509 | 0.090 |
Why?
| | Carcinoma, Small Cell | 1 | 2012 | 172 | 0.090 |
Why?
| | Point Mutation | 1 | 2012 | 234 | 0.090 |
Why?
| | Sutures | 1 | 2011 | 59 | 0.090 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 207 | 0.090 |
Why?
| | Neoplasm Transplantation | 3 | 2020 | 256 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2013 | 254 | 0.090 |
Why?
| | Choice Behavior | 1 | 2012 | 174 | 0.090 |
Why?
| | Gene Expression | 3 | 2019 | 1505 | 0.090 |
Why?
| | Axons | 1 | 2012 | 203 | 0.090 |
Why?
| | Asia | 2 | 2021 | 70 | 0.090 |
Why?
| | Registries | 4 | 2012 | 2006 | 0.090 |
Why?
| | Drainage | 2 | 2008 | 164 | 0.090 |
Why?
| | Panniculitis, Peritoneal | 1 | 2010 | 1 | 0.080 |
Why?
| | Surgery Department, Hospital | 1 | 2010 | 20 | 0.080 |
Why?
| | Antigens | 1 | 2012 | 358 | 0.080 |
Why?
| | Transcriptome | 1 | 2016 | 973 | 0.080 |
Why?
| | Ovarian Neoplasms | 2 | 2007 | 562 | 0.080 |
Why?
| | Liver Function Tests | 2 | 2007 | 114 | 0.080 |
Why?
| | Mesentery | 1 | 2010 | 48 | 0.080 |
Why?
| | Genital Neoplasms, Female | 1 | 2011 | 88 | 0.080 |
Why?
| | Internal-External Control | 1 | 2010 | 71 | 0.080 |
Why?
| | Embolization, Therapeutic | 1 | 2012 | 227 | 0.080 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2009 | 10 | 0.080 |
Why?
| | Pandemics | 3 | 2023 | 1615 | 0.080 |
Why?
| | Morbidity | 4 | 2012 | 321 | 0.080 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2009 | 32 | 0.080 |
Why?
| | Collagen Type IV | 1 | 2009 | 28 | 0.080 |
Why?
| | Cadherins | 1 | 2011 | 205 | 0.080 |
Why?
| | Uncertainty | 1 | 2010 | 125 | 0.080 |
Why?
| | Drug Synergism | 3 | 2007 | 379 | 0.080 |
Why?
| | Sex Factors | 4 | 2022 | 2067 | 0.080 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2006 | 12 | 0.080 |
Why?
| | Adenoma, Liver Cell | 1 | 2009 | 5 | 0.080 |
Why?
| | Hospitals, University | 2 | 2010 | 181 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2008 | 285 | 0.080 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 339 | 0.080 |
Why?
| | Biofilms | 1 | 2011 | 262 | 0.080 |
Why?
| | Chyle | 1 | 2008 | 4 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 348 | 0.080 |
Why?
| | ROC Curve | 2 | 2024 | 543 | 0.080 |
Why?
| | Chylous Ascites | 1 | 2008 | 6 | 0.070 |
Why?
| | Medical Records | 1 | 2009 | 173 | 0.070 |
Why?
| | Suture Techniques | 1 | 2009 | 122 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 176 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2016 | 2833 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2012 | 494 | 0.070 |
Why?
| | Hepatitis, Viral, Human | 1 | 2008 | 26 | 0.070 |
Why?
| | Annexins | 1 | 2008 | 3 | 0.070 |
Why?
| | Laparotomy | 1 | 2008 | 109 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2010 | 295 | 0.070 |
Why?
| | Antibodies | 2 | 2009 | 414 | 0.070 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2007 | 4 | 0.070 |
Why?
| | Erlotinib Hydrochloride | 3 | 2013 | 71 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 1460 | 0.070 |
Why?
| | Gastroscopy | 1 | 2007 | 19 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 614 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 410 | 0.070 |
Why?
| | Gastric Emptying | 1 | 2007 | 38 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 667 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 22 | 0.070 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1502 | 0.070 |
Why?
| | Histiocytosis, Sinus | 1 | 2007 | 8 | 0.070 |
Why?
| | Blood Urea Nitrogen | 1 | 2007 | 53 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 451 | 0.070 |
Why?
| | Transaminases | 1 | 2007 | 24 | 0.070 |
Why?
| | Electrocoagulation | 1 | 2007 | 40 | 0.070 |
Why?
| | Anus Neoplasms | 1 | 2007 | 31 | 0.070 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 129 | 0.070 |
Why?
| | Pyrroles | 1 | 2008 | 211 | 0.070 |
Why?
| | Hormones, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2013 | 1097 | 0.070 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2007 | 52 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 101 | 0.070 |
Why?
| | Receptors, Somatostatin | 1 | 2006 | 26 | 0.070 |
Why?
| | International Agencies | 3 | 2011 | 35 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 279 | 0.070 |
Why?
| | HIV-1 | 1 | 1993 | 862 | 0.070 |
Why?
| | Adrenal Cortex | 1 | 2006 | 29 | 0.070 |
Why?
| | Somatostatin | 1 | 2006 | 62 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 2998 | 0.070 |
Why?
| | Thymidylate Synthase | 1 | 2006 | 12 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1769 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 178 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 156 | 0.060 |
Why?
| | Patient Readmission | 1 | 2012 | 693 | 0.060 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1150 | 0.060 |
Why?
| | Exonucleases | 1 | 2006 | 9 | 0.060 |
Why?
| | Apoptosis | 4 | 2021 | 2542 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2009 | 488 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2013 | 1976 | 0.060 |
Why?
| | Organizational Culture | 2 | 2021 | 144 | 0.060 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 40 | 0.060 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2007 | 211 | 0.060 |
Why?
| | Paraganglioma | 1 | 2006 | 51 | 0.060 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 320 | 0.060 |
Why?
| | Pilot Projects | 3 | 2023 | 1684 | 0.060 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2006 | 148 | 0.060 |
Why?
| | B7-1 Antigen | 1 | 2005 | 58 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 56 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 916 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2008 | 616 | 0.060 |
Why?
| | Hospital Costs | 1 | 2005 | 119 | 0.060 |
Why?
| | Indoles | 1 | 2008 | 411 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 213 | 0.060 |
Why?
| | Sweden | 1 | 2025 | 101 | 0.060 |
Why?
| | Proteomics | 2 | 2008 | 1111 | 0.060 |
Why?
| | Pylorus | 1 | 2024 | 17 | 0.060 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 28 | 0.060 |
Why?
| | Postoperative Period | 2 | 2020 | 344 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 338 | 0.060 |
Why?
| | Galectin 3 | 1 | 2004 | 21 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 143 | 0.060 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1061 | 0.060 |
Why?
| | Neuropilin-1 | 1 | 2004 | 9 | 0.060 |
Why?
| | Probability | 1 | 2005 | 311 | 0.060 |
Why?
| | Mesenteric Artery, Superior | 2 | 2020 | 15 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2018 | 3528 | 0.060 |
Why?
| | Celiac Artery | 2 | 2020 | 17 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2007 | 211 | 0.060 |
Why?
| | Age Distribution | 1 | 2005 | 391 | 0.050 |
Why?
| | Camptothecin | 1 | 2004 | 116 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 378 | 0.050 |
Why?
| | Canada | 2 | 2018 | 417 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 4 | 1985 | 158 | 0.050 |
Why?
| | Protein Array Analysis | 1 | 2004 | 57 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 214 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 658 | 0.050 |
Why?
| | Proteome | 1 | 2008 | 473 | 0.050 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 41 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2025 | 226 | 0.050 |
Why?
| | Cholecystitis | 1 | 2003 | 24 | 0.050 |
Why?
| | Pyridines | 1 | 2007 | 504 | 0.050 |
Why?
| | Child | 6 | 2009 | 21896 | 0.050 |
Why?
| | Genomic Instability | 1 | 2003 | 54 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 313 | 0.050 |
Why?
| | Transcription Factors | 1 | 2011 | 1715 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2025 | 565 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2003 | 168 | 0.050 |
Why?
| | Mass Screening | 2 | 2010 | 1262 | 0.050 |
Why?
| | Reproducibility of Results | 4 | 2014 | 3282 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 398 | 0.050 |
Why?
| | Postoperative Hemorrhage | 1 | 2023 | 88 | 0.050 |
Why?
| | Health Care Costs | 1 | 2005 | 386 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 11 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 267 | 0.050 |
Why?
| | Biopsy | 3 | 2013 | 1130 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2024 | 300 | 0.050 |
Why?
| | Chromogranins | 2 | 2012 | 15 | 0.050 |
Why?
| | Pneumonectomy | 1 | 2023 | 154 | 0.050 |
Why?
| | MutL Protein Homolog 1 | 2 | 2016 | 12 | 0.050 |
Why?
| | X-linked Nuclear Protein | 2 | 2012 | 9 | 0.050 |
Why?
| | Radiotherapy, Conformal | 2 | 2012 | 70 | 0.050 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 560 | 0.050 |
Why?
| | Co-Repressor Proteins | 2 | 2012 | 18 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 683 | 0.050 |
Why?
| | Jaundice | 2 | 2011 | 14 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 303 | 0.050 |
Why?
| | Chemokines | 1 | 2022 | 229 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 75 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 617 | 0.050 |
Why?
| | Prevalence | 2 | 2023 | 2709 | 0.050 |
Why?
| | Neuropeptides | 1 | 2021 | 75 | 0.050 |
Why?
| | Clone Cells | 2 | 2012 | 266 | 0.040 |
Why?
| | Smoking | 1 | 2009 | 1633 | 0.040 |
Why?
| | Antigens, CD | 1 | 2024 | 524 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 220 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 32 | 0.040 |
Why?
| | Pedigree | 2 | 2012 | 509 | 0.040 |
Why?
| | Phenotype | 3 | 2015 | 3201 | 0.040 |
Why?
| | Chromatin Assembly and Disassembly | 2 | 2011 | 106 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 8 | 0.040 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2000 | 10 | 0.040 |
Why?
| | Portal System | 1 | 2020 | 14 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 145 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1945 | 0.040 |
Why?
| | Contrast Media | 3 | 2010 | 462 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 624 | 0.040 |
Why?
| | Terminology as Topic | 2 | 2013 | 212 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 85 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 73 | 0.040 |
Why?
| | Educational Status | 1 | 2022 | 482 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.040 |
Why?
| | Molecular Chaperones | 2 | 2012 | 196 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2020 | 201 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 665 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2025 | 2182 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 531 | 0.040 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2012 | 57 | 0.040 |
Why?
| | Mitochondria | 1 | 2006 | 938 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 331 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1000 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 114 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 366 | 0.040 |
Why?
| | Drug Utilization Review | 1 | 2019 | 56 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 734 | 0.040 |
Why?
| | Abdominal Pain | 2 | 2011 | 146 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 277 | 0.040 |
Why?
| | Antigens, Differentiation | 2 | 2011 | 83 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 146 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2844 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1988 | 22 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 319 | 0.040 |
Why?
| | Organizational Innovation | 2 | 2010 | 139 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1417 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 811 | 0.040 |
Why?
| | Ketoconazole | 1 | 1997 | 4 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 849 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 329 | 0.040 |
Why?
| | HIV Infections | 1 | 1993 | 2822 | 0.040 |
Why?
| | Inflammation | 2 | 2006 | 2817 | 0.040 |
Why?
| | Immunocompetence | 1 | 1997 | 42 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 2078 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 543 | 0.040 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 310 | 0.040 |
Why?
| | Up-Regulation | 3 | 2007 | 846 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2013 | 2837 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.030 |
Why?
| | Sclerosis | 2 | 2010 | 13 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2019 | 277 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 678 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2017 | 127 | 0.030 |
Why?
| | Clinical Audit | 1 | 2016 | 13 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 362 | 0.030 |
Why?
| | MutS Homolog 2 Protein | 1 | 2016 | 15 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 567 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 889 | 0.030 |
Why?
| | Ultrasonography | 2 | 2011 | 749 | 0.030 |
Why?
| | Obesity | 1 | 2010 | 2966 | 0.030 |
Why?
| | Patient Satisfaction | 2 | 2012 | 657 | 0.030 |
Why?
| | Protein Binding | 2 | 2022 | 2222 | 0.030 |
Why?
| | Cyclosporine | 1 | 1997 | 268 | 0.030 |
Why?
| | Adenosine | 2 | 1988 | 227 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1086 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 40 | 0.030 |
Why?
| | Child, Preschool | 3 | 2024 | 11013 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2021 | 552 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 24 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2014 | 219 | 0.030 |
Why?
| | Microsomes, Liver | 3 | 1985 | 87 | 0.030 |
Why?
| | Metaplasia | 2 | 2006 | 60 | 0.030 |
Why?
| | Margins of Excision | 1 | 2016 | 50 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 741 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 779 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1026 | 0.030 |
Why?
| | Pain Management | 1 | 2019 | 360 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 80 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2901 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2008 | 816 | 0.030 |
Why?
| | Gadolinium DTPA | 2 | 2006 | 70 | 0.030 |
Why?
| | HCT116 Cells | 2 | 2006 | 80 | 0.030 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 51 | 0.030 |
Why?
| | Infection Control | 1 | 2016 | 158 | 0.030 |
Why?
| | Vascular Patency | 1 | 2015 | 105 | 0.030 |
Why?
| | Carbon Tetrachloride | 2 | 1985 | 13 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 133 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2016 | 229 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1018 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2006 | 188 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 978 | 0.030 |
Why?
| | Patient Transfer | 1 | 2016 | 165 | 0.030 |
Why?
| | Phosgene | 2 | 1984 | 7 | 0.030 |
Why?
| | Machine Learning | 1 | 2019 | 487 | 0.030 |
Why?
| | Weight Loss | 2 | 2011 | 765 | 0.030 |
Why?
| | Medical Oncology | 1 | 2016 | 289 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 345 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2013 | 28 | 0.030 |
Why?
| | Chromosomes, Human, X | 1 | 2013 | 75 | 0.030 |
Why?
| | Immunologic Techniques | 1 | 1993 | 40 | 0.030 |
Why?
| | Proteins | 2 | 2012 | 1012 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 948 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2012 | 2 | 0.020 |
Why?
| | Diabetes Mellitus | 2 | 2012 | 1033 | 0.020 |
Why?
| | Heredity | 1 | 2012 | 13 | 0.020 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2012 | 17 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1993 | 124 | 0.020 |
Why?
| | Review Literature as Topic | 1 | 2012 | 74 | 0.020 |
Why?
| | Laser Capture Microdissection | 1 | 2012 | 33 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2011 | 16 | 0.020 |
Why?
| | Codon | 1 | 2012 | 90 | 0.020 |
Why?
| | Influenza A virus | 1 | 1993 | 109 | 0.020 |
Why?
| | Gene Dosage | 1 | 2012 | 148 | 0.020 |
Why?
| | Xanthines | 2 | 1988 | 20 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 67 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 129 | 0.020 |
Why?
| | Periodic Acid-Schiff Reaction | 1 | 2011 | 3 | 0.020 |
Why?
| | Cytodiagnosis | 1 | 2011 | 33 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2011 | 59 | 0.020 |
Why?
| | China | 1 | 2012 | 218 | 0.020 |
Why?
| | Ablation Techniques | 1 | 2011 | 35 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2011 | 150 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2012 | 170 | 0.020 |
Why?
| | Mitosis | 1 | 2012 | 193 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 87 | 0.020 |
Why?
| | Frozen Sections | 1 | 2011 | 26 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 620 | 0.020 |
Why?
| | Neprilysin | 1 | 2011 | 47 | 0.020 |
Why?
| | Minnesota | 1 | 2011 | 161 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 658 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 99 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 305 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1993 | 362 | 0.020 |
Why?
| | Gene Frequency | 1 | 2012 | 521 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 135 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 353 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 85 | 0.020 |
Why?
| | Carcinoma, Ductal | 1 | 2010 | 11 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 2010 | 31 | 0.020 |
Why?
| | Portugal | 1 | 2010 | 10 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1993 | 368 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2011 | 175 | 0.020 |
Why?
| | Organizational Case Studies | 1 | 2010 | 77 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 142 | 0.020 |
Why?
| | Personnel Turnover | 1 | 2010 | 41 | 0.020 |
Why?
| | Fanconi Anemia | 1 | 2010 | 11 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4046 | 0.020 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2010 | 10 | 0.020 |
Why?
| | Genes, p16 | 1 | 2010 | 20 | 0.020 |
Why?
| | Genes, BRCA2 | 1 | 2010 | 29 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2010 | 56 | 0.020 |
Why?
| | Gastric Bypass | 1 | 2011 | 118 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 413 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2011 | 162 | 0.020 |
Why?
| | Attitude to Death | 1 | 2010 | 69 | 0.020 |
Why?
| | Forms and Records Control | 1 | 2009 | 23 | 0.020 |
Why?
| | Professional Practice | 1 | 2009 | 64 | 0.020 |
Why?
| | Diagnosis-Related Groups | 1 | 2009 | 29 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 59 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2010 | 171 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2009 | 18 | 0.020 |
Why?
| | Tamoxifen | 1 | 2010 | 199 | 0.020 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 78 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2010 | 299 | 0.020 |
Why?
| | beta Catenin | 1 | 2011 | 251 | 0.020 |
Why?
| | Genes, p53 | 1 | 2009 | 72 | 0.020 |
Why?
| | Genes, ras | 1 | 2009 | 96 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 171 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2003 | 1255 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 366 | 0.020 |
Why?
| | Postoperative Care | 1 | 2010 | 258 | 0.020 |
Why?
| | Family Health | 1 | 2009 | 200 | 0.020 |
Why?
| | Molecular Probes | 1 | 2008 | 36 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 343 | 0.020 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2012 | 290 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 615 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 2010 | 153 | 0.020 |
Why?
| | Claudins | 1 | 2008 | 25 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2180 | 0.020 |
Why?
| | Anticoagulants | 1 | 2013 | 662 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 82 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 385 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 328 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 393 | 0.020 |
Why?
| | Disease Management | 1 | 2012 | 624 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2011 | 301 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2011 | 536 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 1058 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 72 | 0.020 |
Why?
| | Chronic Disease | 2 | 2003 | 1773 | 0.020 |
Why?
| | Cell Line | 1 | 1993 | 2847 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1906 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 321 | 0.020 |
Why?
| | Population Surveillance | 1 | 2010 | 471 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 2183 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 133 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2009 | 193 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 111 | 0.020 |
Why?
| | Folic Acid Antagonists | 1 | 2006 | 9 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4491 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2008 | 228 | 0.020 |
Why?
| | Tetrahydrofolates | 1 | 2006 | 18 | 0.020 |
Why?
| | Gallbladder | 1 | 2006 | 19 | 0.020 |
Why?
| | Lymphotoxin beta Receptor | 1 | 2006 | 2 | 0.020 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2006 | 4 | 0.020 |
Why?
| | Medicare | 1 | 2012 | 745 | 0.020 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2006 | 10 | 0.020 |
Why?
| | Evidence-Based Practice | 1 | 2009 | 222 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2006 | 6 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 444 | 0.020 |
Why?
| | Concanavalin A | 1 | 2006 | 76 | 0.020 |
Why?
| | Antigens, Ly | 1 | 2006 | 44 | 0.020 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 18 | 0.020 |
Why?
| | Claudin-4 | 1 | 2006 | 15 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 544 | 0.020 |
Why?
| | Halothane | 1 | 1985 | 7 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2006 | 83 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2006 | 116 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2006 | 154 | 0.020 |
Why?
| | Granzymes | 1 | 2006 | 49 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 165 | 0.020 |
Why?
| | Macrophages | 1 | 2013 | 1547 | 0.020 |
Why?
| | CA-125 Antigen | 1 | 2005 | 14 | 0.020 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 20 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 248 | 0.020 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2005 | 15 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2006 | 164 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 596 | 0.020 |
Why?
| | Homeostasis | 1 | 2009 | 622 | 0.010 |
Why?
| | Iodized Oil | 1 | 2005 | 4 | 0.010 |
Why?
| | Overweight | 1 | 2010 | 554 | 0.010 |
Why?
| | Exoribonucleases | 1 | 2006 | 49 | 0.010 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 123 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 1037 | 0.010 |
Why?
| | Epithelium | 1 | 2006 | 315 | 0.010 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2004 | 16 | 0.010 |
Why?
| | Methotrexate | 1 | 2006 | 255 | 0.010 |
Why?
| | Family | 1 | 2009 | 667 | 0.010 |
Why?
| | Heme | 1 | 1985 | 79 | 0.010 |
Why?
| | bcl-X Protein | 1 | 2004 | 43 | 0.010 |
Why?
| | Janus Kinase 2 | 1 | 2004 | 32 | 0.010 |
Why?
| | Bile | 1 | 2004 | 34 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 497 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 1434 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 247 | 0.010 |
Why?
| | Biliary Tract Diseases | 1 | 2004 | 39 | 0.010 |
Why?
| | Histocytological Preparation Techniques | 1 | 2004 | 2 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 1987 | 509 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1460 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 1060 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1227 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 2143 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 49 | 0.010 |
Why?
| | Methyl n-Butyl Ketone | 1 | 1983 | 1 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2005 | 114 | 0.010 |
Why?
| | Chloroform | 1 | 1983 | 4 | 0.010 |
Why?
| | Phenobarbital | 1 | 1983 | 19 | 0.010 |
Why?
| | Paraffin Embedding | 1 | 2004 | 32 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1108 | 0.010 |
Why?
| | Chile | 1 | 2003 | 24 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1041 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 234 | 0.010 |
Why?
| | Ketones | 1 | 1983 | 51 | 0.010 |
Why?
| | Rats | 6 | 1988 | 5675 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2003 | 318 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 2351 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2009 | 1160 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 765 | 0.010 |
Why?
| | Rats, Inbred Strains | 3 | 1985 | 369 | 0.010 |
Why?
| | Physicians | 1 | 2009 | 902 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2000 | 41 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2110 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 770 | 0.010 |
Why?
| | Phylogeny | 1 | 2003 | 897 | 0.010 |
Why?
| | Image Enhancement | 1 | 2000 | 194 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5398 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6043 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1997 | 50 | 0.010 |
Why?
| | Antimetabolites | 1 | 1997 | 23 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1997 | 416 | 0.010 |
Why?
| | Drug Interactions | 1 | 1997 | 409 | 0.010 |
Why?
| | Infant | 1 | 2009 | 9408 | 0.010 |
Why?
| | Lymphogranuloma Venereum | 1 | 1951 | 2 | 0.010 |
Why?
| | Neck | 1 | 1951 | 101 | 0.010 |
Why?
| | Phenylisopropyladenosine | 1 | 1987 | 6 | 0.000 |
Why?
| | Chemistry | 1 | 1987 | 46 | 0.000 |
Why?
| | Chemical Phenomena | 1 | 1987 | 85 | 0.000 |
Why?
| | Diglycerides | 1 | 1987 | 61 | 0.000 |
Why?
| | Phosphatidylethanolamines | 1 | 1987 | 77 | 0.000 |
Why?
| | Prodrugs | 1 | 1987 | 49 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1988 | 586 | 0.000 |
Why?
| | Aniline Compounds | 1 | 1987 | 102 | 0.000 |
Why?
| | Electrophoresis | 1 | 1985 | 33 | 0.000 |
Why?
| | Acetylation | 1 | 1985 | 254 | 0.000 |
Why?
| | Fatty Acids | 1 | 1987 | 443 | 0.000 |
Why?
| | Cerebral Cortex | 1 | 1987 | 459 | 0.000 |
Why?
| | Benzphetamine | 1 | 1983 | 1 | 0.000 |
Why?
| | Cell Membrane | 1 | 1987 | 751 | 0.000 |
Why?
| | Chromatography, Ion Exchange | 1 | 1983 | 54 | 0.000 |
Why?
| | Oxidation-Reduction | 1 | 1984 | 1059 | 0.000 |
Why?
| | Oxygen | 1 | 1984 | 943 | 0.000 |
Why?
|
|
Schulick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|